Patents by Inventor Marianne Bruggemann

Marianne Bruggemann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200163316
    Abstract: The invention relates to transgenic animals useful for optimal production of functional immunoglobulins with human idiotypes.
    Type: Application
    Filed: January 19, 2018
    Publication date: May 28, 2020
    Inventors: Roland BUELOW, Marianne BRUGGEMANN, Biao MA, Michael J. OSBORN
  • Patent number: 10385132
    Abstract: The invention relates to polynucleotides, particularly chimeric polynucleotides useful for optimal production of functional immunoglobulins with human idiotypes in rodents. The invention further relates to rodents comprising such polynucleotides.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: August 20, 2019
    Assignee: OPEN MONOCLONAL TECHNOLOGY, INC.
    Inventors: Marianne Bruggemann, Roland Buelow, Michael J. Osborn, Biao Ma
  • Publication number: 20190225671
    Abstract: Human or chimeric heavy chain-only antibodies are provided, in the native amino acid residue at the first position of the fourth framework region (FR4) of said HCAb is substituted by a different amino acid residue that is capable of disrupting a surface-exposed hydrophobic patch comprising or associated with the native amino acid residue at that position.
    Type: Application
    Filed: August 22, 2017
    Publication date: July 25, 2019
    Inventors: Wim van Schooten, Nathan Trinklein, Shelley Force-Aldred, Marianne Bruggemann, Mike Osborn
  • Patent number: 10194645
    Abstract: The present invention provides in a first aspect a mouse in which the ? (lambda) light chain locus has been functionally silenced. In one embodiment, the mouse ? light chain locus was functional silenced by deletion of gene segments coding for the ? light chain locus. In a further aspect, a mouse containing functionally silenced ? and ? (kappa) L chain loci was produced. The invention is useful for the production of antibodies, for example heterologous antibodies, including heavy chain only antibodies.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: February 5, 2019
    Assignee: Crescendo Biologics Limited
    Inventors: Marianne Brüggemann, Xiangang Zou
  • Publication number: 20170174770
    Abstract: The invention relates to polynucleotides, particularly chimeric polynucleotides useful for optimal production of functional immunoglobulins with human idiotypes in rodents. The invention further relates to rodents comprising such polynucleotides.
    Type: Application
    Filed: October 24, 2016
    Publication date: June 22, 2017
    Inventors: Marianne BRUGGEMANN, Roland BUELOW, Michael J. OSBORN, Biao MA
  • Publication number: 20170049083
    Abstract: The present invention provides in a first aspect a mouse in which the ? (lambda) light chain locus has been functionally silenced. In one embodiment, the mouse ? light chain locus was functional silenced by deletion of gene segments coding for the ? light chain locus. In a further aspect, a mouse containing functionally silenced ? and ? (kappa) L chain loci was produced. The invention is useful for the production of antibodies, for example heterologous antibodies, including heavy chain only antibodies.
    Type: Application
    Filed: August 8, 2016
    Publication date: February 23, 2017
    Applicant: Crescendo Biologics Limited
    Inventors: Marianne Brüggemann, Xiangang Zou
  • Patent number: 9475859
    Abstract: The invention relates to polynucleotides, particularly chimeric polynucleotides useful for optimal production of functional immunoglobulins with human idiotypes in rodents. The invention further relates to rodents comprising such polynucleotides.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: October 25, 2016
    Assignee: OMT, Inc.
    Inventors: Marianne Bruggemann, Roland Buelow, Michael J. Osborn, Biao Ma
  • Patent number: 9439405
    Abstract: The present invention provides in a first aspect a mouse in which the ? (lambda) light chain locus has been functionally silenced. In one embodiment, the mouse ? light chain locus was functional silenced by deletion of acne segments coding for the ? light chain locus. In a further aspect, a mouse containing functionally silenced ? and ? (kappa) L chain loci was produced. The invention is useful for the production of antibodies, for example heterologous antibodies, including heavy chain only antibodies.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: September 13, 2016
    Assignee: Crescendo Biologics Limited
    Inventors: Marianne Brüggemann, Xiangang Zou
  • Publication number: 20150113668
    Abstract: The invention relates to polynucleotides, particularly chimeric polynucleotides useful for optimal production of functional immunoglobulins with human idiotypes in rodents. The invention further relates to rodents comprising such polynucleotides.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Marianne BRUGGEMANN, Roland BUELOW, Michael J. OSBORN, Biao MA
  • Patent number: 8367888
    Abstract: The present invention provides in a first aspect a mouse in which the ? (lambda) light chain locus has been functionally silenced. In one embodiment, the mouse ? light chain locus was functional silenced by deletion of gene segments coding for the ? light chain locus. In a further aspect, a mouse containing functionally silenced ? and ? (kappa) L chain loci was produced. The invention is useful for the production of antibodies, for example heterologous antibodies, including heavy chain only antibodies.
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: February 5, 2013
    Assignee: Crescendo Biologics Limited
    Inventors: Marianne Brüggemann, Xiangang Zou
  • Patent number: 8329981
    Abstract: A genetically modified mouse characterized in that it does not comprise a nucleic acid sequence which itself encodes any endogenous immunoglobulin heavy chain constant region locus polypeptide.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: December 11, 2012
    Assignee: Crescendo Biologics Limited
    Inventor: Marianne Bruggemann
  • Publication number: 20110277047
    Abstract: A genetically modified mouse characterised in that it does not comprise a nucleic acid sequence which itself encodes any endogenous immunoglobulin heavy chain constant region locus polypeptide
    Type: Application
    Filed: April 6, 2011
    Publication date: November 10, 2011
    Inventor: Marianne Bruggemann
  • Patent number: 7932431
    Abstract: A genetically modified non-human mammal or cell characterised in that it does not comprise a nucleic acid sequence which itself encodes any endogenous immunoglobulin heavy chain constant region locus polypeptide.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: April 26, 2011
    Assignee: Crescendo Biologics Limited
    Inventor: Marianne Bruggemann
  • Publication number: 20110093961
    Abstract: The present invention provides in a first aspect a mouse in which the ? (lambda) light chain locus has been functionally silenced. In one embodiment, the mouse ? light chain locus was functional silenced by deletion of gene segments coding for the ? light chain locus. In a further aspect, a mouse containing functionally silenced ? and ? (kappa) L chain loci was produced. The invention is useful for the production of antibodies, for example heterologous antibodies, including heavy chain only antibodies.
    Type: Application
    Filed: June 1, 2009
    Publication date: April 21, 2011
    Applicant: TRANSLOCUS LIMITED
    Inventors: MARIANNE BRUGGEMANN, XIANGANG ZOU
  • Publication number: 20100122358
    Abstract: The invention relates to mice having functionally silenced endogenous lambda (?) and kappa (?) L-chain loci, comprising antibody-producing cells in which the CH1 domain is functionally silenced, either via spontaneous processes in somatic antibody-producing cells or due to germline deletion of the CH1 domain. Mice of the invention are capable of producing H-chain-only antibody lacking a functional CH1 domain; transgenic human heavy-chain-only antibodies lacking a functional CH1 domain can be produced following insertion into the mouse of an artificial locus with human heavy chain V, D and J segments and a constant region, which is preferably a modified constant region with alterations in, around or upstream of a CH1 domain and/or removal of a CH1 domain.
    Type: Application
    Filed: June 8, 2009
    Publication date: May 13, 2010
    Applicant: Crescendo Biologics Limited
    Inventors: Marianne Brüggemann, Xiangang Zou, Louise Matheson, Michael Osborn
  • Publication number: 20060236418
    Abstract: A genetically modified non-human mammal or cell characterised in that it does not comprise a nucleic acid sequence which itself encodes any endogenous immunoglobulin heavy chain constant region locus polypeptide.
    Type: Application
    Filed: February 26, 2004
    Publication date: October 19, 2006
    Applicant: Babraham Institute
    Inventor: Marianne Bruggemann
  • Patent number: 6998514
    Abstract: In humans, approximately 60% of expressed immunoglobulin light chains are of the Kappa type and 40% of the Lambda type. In mice, there is almost no expression from the Lambda locus and over 95% of light chains are of Kappa type. The present invention discloses, among other things, transgenic mice carrying most of the human Ig Lambda light chain locus in their genome. The resulting mice express light chains with Kappa/Lambda ratio similar to the human ratio. Breeding of HuIg Lamda mice to Kappa-deficient mice also is described, as well as the generation of human monoclonal antibodies from transgenic mice with human Ig Lambda locus.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: February 14, 2006
    Assignee: Babraham Institute
    Inventor: Marianne Bruggemann
  • Publication number: 20040231012
    Abstract: In humans, approximately 60% of expressed immunoglobulin light chains are of the Kappa type and 40% of the Lambda type. In mice, there is almost no expression from the Lambda locus and over 95% of light chains are of Kappa type. The present invention discloses, among other things, transgenic mice carrying most of the human Ig Lambda light chain locus in their genome. The resulting mice express light chains with Kappa/Lambda ratio similar to the human ratio. Breeding of HuIg Lamda mice to Kappa-deficient mice also is described, as well as the generation of human monoclonal antibodies from transgenic mice with human Ig Lambda locus.
    Type: Application
    Filed: January 9, 2004
    Publication date: November 18, 2004
    Applicant: The Babraham Institute
    Inventor: Marianne Bruggemann
  • Publication number: 20020088016
    Abstract: In humans, approximately 60% of expressed immunoglobulin light chains are of the Kappa type and 40% of the Lambda type. In mice, there is almost no expression from the Lambda locus and over 95% of light chains are of Kappa type. The present invention discloses, among other things, transgenic mice carrying most of the human Ig Lambda light chain locus in their genome. The resulting mice express light chains with Kappa/Lambda ratio similar to the human ratio. Breeding of HuIg Lamda mice to Kappa-deficient mice also is described, as well as the generation of human monoclonal antibodies from transgenic mice with human Ig Lambda locus.
    Type: Application
    Filed: December 13, 2000
    Publication date: July 4, 2002
    Inventor: Marianne Bruggemann
  • Patent number: 6348349
    Abstract: Embryonic stem cells or other cells (not prokaryotic or yeast) that are essentially free of yeast DNA are prepared from suitably marked yeast artificial chromosomes and used to transfer DNA segments of considerable size into organisms.
    Type: Grant
    Filed: July 6, 1998
    Date of Patent: February 19, 2002
    Assignee: The Babraham Institute
    Inventor: Marianne Bruggemann